← Back to Search

Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders for Misophonia

N/A
Waitlist Available
Led By M. Zachary Rosenthal, PhD
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 weeks
Awards & highlights

Study Summary

Exploring the Acceptability and Efficacy of a Transdiagnostic Treatment for Misophonia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in anger as measured by the PANAS Hostility Scale
Change in anxiety as measured by the Overall Anxiety Severity and Impairment Scale
Change in depression as measured by the Overall Depression Severity and Impairment Scale
+9 more
Secondary outcome measures
Number of patients who report a change in attentional control as measured by the Digit Span Test
Number of patients who report a change in attentional control as measured by the Trail Making Test
Number of patients who report a change in cognitive flexibility as measured by the Stroop test
+3 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Phase 2: Revised Unified Protocol, 4 week baselineExperimental Treatment1 Intervention
Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
Group II: Phase 2: Revised Unified Protocol, 2 week baselineExperimental Treatment1 Intervention
Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
Group III: Phase 1: Unified Protocol, 2 week baselineExperimental Treatment1 Intervention
Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
Group IV: Phase 1: Experimental: Unified Protocol, 4 week baselineExperimental Treatment1 Intervention
Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
2020
N/A
~110
Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
2020
N/A
~20

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,363 Previous Clinical Trials
3,420,468 Total Patients Enrolled
3 Trials studying Misophonia
131 Patients Enrolled for Misophonia
M. Zachary Rosenthal, PhDPrincipal InvestigatorDuke University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Exploring the Acceptability and Efficacy of a Transdiagnostic Treatment for Misophonia
2020. "Exploring the Acceptability and Efficacy of a Transdiagnostic Treatment for Misophonia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04612374.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top